Defining the clinical course of multiple sclerosisFred Lublin, Chris H. Polman, Stephen C. Reingold et al.|Neurology|2014Cited by 3.1k
Type II monocytes modulate T cell–mediated central nervous system autoimmune diseaseMartin S. Weber, Scott S. Zamvil, Thomas Prod’homme et al.|Nature Medicine|2007Cited by 448
Treatment of neuromyelitis optica: Review and recommendationsDorlan Kimbrough, Dean M. Wingerchuk, Jacqueline Palace et al.|Multiple Sclerosis and Related Disorders|2012Cited by 263
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisRobert Zivadinov, Omar Khan, Anthony T. Reder et al.|Neurology|2008Cited by 261
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, Erik Wallström, David K.B. Li et al.|The Lancet Neurology|2013Cited by 233